HC Wainwright Predicts Cibus’ FY2029 Earnings (NASDAQ:CBUS)

Cibus, Inc. (NASDAQ:CBUS) – Research analysts at HC Wainwright decreased their FY2029 earnings per share estimates for Cibus in a note issued to investors on Friday, August 14th. HC Wainwright analyst A. Dayal now expects that the company will earn $0.27 per share for the year, down from their previous estimate of $0.28. The consensus estimate for Cibus’ current full-year earnings is ($1.05) per share. HC Wainwright also issued estimates for Cibus’ FY2030 earnings at $2.08 EPS.

Cibus (NASDAQ:CBUS) last released its earnings results on Thursday, August 13th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.10). The business had revenue of $0.99 million during the quarter, compared to analyst estimates of $1.70 million. Cibus had a negative net margin of 2,258.89% and a negative return on equity of 287.03%.

Several other brokerages have also recently commented on CBUS. Weiss Ratings cut shares of Cibus from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 29th. Wall Street Zen upgraded shares of Cibus from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Cibus has a consensus rating of “Hold” and a consensus price target of $9.00.

Cibus Stock Down 5.6%

NASDAQ:CBUS opened at $1.67 on Monday. Cibus has a fifty-two week low of $1.09 and a fifty-two week high of $4.19. The stock has a market cap of $127.47 million, a PE ratio of -1.01 and a beta of 1.61. The firm’s fifty day simple moving average is $1.66 and its 200-day simple moving average is $1.97.

Institutional Trading of Cibus

A number of institutional investors have recently bought and sold shares of CBUS. PACK Private Wealth LLC acquired a new stake in Cibus in the fourth quarter valued at $27,000. Dimensional Fund Advisors LP acquired a new position in shares of Cibus during the 1st quarter worth $33,000. Qube Research & Technologies Ltd acquired a new position in shares of Cibus during the 2nd quarter worth $39,000. Rockland Trust Co. purchased a new stake in shares of Cibus in the 2nd quarter worth about $41,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Cibus in the 3rd quarter worth about $62,000. 33.81% of the stock is currently owned by hedge funds and other institutional investors.

Cibus Company Profile

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.